Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HIV DNA vaccine - ValiRx

Drug Profile

HIV DNA vaccine - ValiRx

Alternative Names: DNA-GTU vaccine; FIT-06; GTU MultiHIV; GTU-multi-HIV B clade DNA vaccine; GTU®-multiHIV B Clade Vaccine

Latest Information Update: 10 May 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator FIT Biotech
  • Developer European HIV Vaccine Alliance; FIT Biotech; Imperial College of Science, Technology and Medicine
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II HIV infections

Most Recent Events

  • 02 May 2019 ValiRx acquires global granted patents and intellectual property assets from FIT Biotech
  • 28 Nov 2018 Phase-I/II clinical trials in HIV infections in Switzerland (IM) (NCT02972450)
  • 06 Sep 2018 FIT Biotech, European HIV Vaccine Alliance Consortium, Imperial College London and Inserm-ANRS plan the phase I/II EHVAT01 trial for HIV infections in United Kingdom, France, Switzerland and Europe (IM, Injection) in the fourth quarter of 2018 , (NCT02972450)
Restricted Access

If your organization has a subscription then there are several options available to help you access AdisInsight while working remotely. Contact us at AsktheExpert.AdisInsight@springer.com to find out more.
Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top